| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | -0.0029 | 0.9 |